News | October 18, 2012

Accuray CEO Resigns, Board Appoints Successor for Next Phase of Growth

October 18, 2012 — Accuray Inc. announced the resignation of Euan S. Thomson as president and CEO, and director of the board. Accuray's board has appointed Joshua H. Levine as his successor, effective immediately. Thomson is anticipated to continue in a consulting role with the company.

Thomson joined Accuray in March 2002 as CEO, was appointed president in September 2002 and served on the board of directors. During his tenure, Thomson expanded the radiosurgery market with the company's flagship product, the CyberKnife system. He took the company public in February 2007 and led the company through the transformational acquisition of TomoTherapy in 2011. The acquisition of TomoTherapy added the TomoTherapy system to the company's product portfolio, which expanded Accuray into the radiation therapy market.

"I want to thank the board, Accuray employees and customers for their support and encouragement over the last 10 years as we together changed the way people think about treating cancer patients," said Thomson. "It's been a fulfilling experience, but I feel that after being CEO for 10 years, a change in leadership is healthy for the organization. It's time for change, for both the company and me."

"Euan was instrumental in growing Accuray's installed base from approximately 5 to more than 642 systems, and growing the company from approximately 75 to over 1,100 employees," said Louis J. Lavigne Jr., chairperson of the board. "The board would like to thank Euan for his 10 years of service and leading the company through the acquisition of TomoTherapy. With the acquisition of TomoTherapy we are now ready for the next stage of growth. Capitalizing on the progress made by Euan, the board attracted Joshua Levine, who the board believes is an experienced, commercially oriented CEO with diverse global healthcare experience necessary to lead the company to the next level of success."

Levine previously was CEO of Mentor Corp. where he led the company through a strategic transformation and was instrumental in its sale to a franchise of Johnson & Johnson in January 2009, and more recently was CEO of Immucor Corp. until October 2011, when it was acquired by TPG Capital.

"I am honored and excited about the opportunity to lead this great organization through its next phase of growth. Accuray has a history of technical innovations in the radiation oncology field that have helped support the personalized clinical needs of cancer patients and the radiation oncologists who treat them. I look forward to working with all of Accuray's talented and dedicated employees to help build profitable growth producing value for all of the company's constituents – shareholders, customers and employees alike," said Levine.

For more information: www.accuray.com

Related Content

Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer
The results of an online questionnaire of 609 breast cancer survivors in the U.S. suggest that nearly half of patients experienced delays in care during the early weeks of the COVID-19 pandemic.

Getty Images

News | Coronavirus (COVID-19) | August 19, 2020
August 19, 2020 — The...
Smoking is strongly linked to lower use of cancer screening services by women, and more advanced disease once cancer is diagnosed, reveals research published in the online journal BMJ Open.

Getty Images

News | Lung Imaging | August 14, 2020
August 14, 2020 — Smoking is strongly linked to lower use of...
Rafael Rivero, M.D., Global Head of Medical Affairs at MSI, said: "The importance of MyoStrain cannot be understated because of the test's immense clinical value and ability to quantify intramyocardial dysfunction across 48 segments of the heart. In a six-heartbeat MRI scan, MyoStrain arms physicians with novel clinical information about a patient's heart health."
News | Cardiac Imaging | August 11, 2020
August 11, 2020 — Myocardial Solutions, Inc. and United Imaging, Inc.